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ABSTRACT
Objectives: The aim was to explore the prognostic significance of IL-6 and 
markers of systemic inflammatory response (SIR), in particular C-reactive protein 
(CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population 
and according to RAS and BRAF mutation status.
Results: High levels of pretreatment serum IL-6 or CRP were associated with 
impaired outcome, in terms of reduced PFS and OS. Patients with low versus high 
serum IL-6 levels had median OS of 26.0 versus 16.6 months, respectively (P < 0.001). 
Stratified according to increasing CRP levels, median OS varied from 24.3 months 
to 12.3 months, (P < 0.001). IL-6 and CRP levels affected overall prognosis also in 
adjusted analyses. The effect of IL-6 was particularly pronounced in patients with 
BRAF mutation (interaction P = 0.004). 
Materials and Methods: IL-6 and CRP were determined in pre-treatment serum 
samples from 393 patients included in the NORDIC-VII trial, in which patients with 
mCRC received first line treatment. The effect of serum IL-6 and CRP on progression-
free survival (PFS) and overall survival (OS) was estimated.
Conclusions: High baseline serum consentrations of IL-6 or CRP were associated 
with impaired prognosis in mCRC. IL-6 and CRP give independent prognostic 
information in addition to RAS and BRAF mutation status.
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INTRODUCTION
Colorectal cancer (CRC) is worldwide the second 
most commonly diagnosed cancer in females and the 
third in males. Almost half of the patients diagnosed 
with CRC have or will develop distant metastases [1]. 
Metastatic CRC (mCRC) follows widely differing clinical 
courses, depending on genetic and non-genetic factors. 
A large body of evidence indicates that an inflammatory 
microenvironment is of decisive importance for the 
progression of tumors and the clinical outcome of 
cancers [2–6], including CRC [7]. It would be valuable 
to have easily accessible biomarkers for monitoring 
of the inflammatory status of the cancer, and several 
inflammation-based factors have been evaluated for their 
usefulness as prognostic biomarkers [6, 8, 9]. 
While critical mutations are the underlying drivers 
in oncogenesis [10], interaction between the transformed 
cells and the microenvironment is necessary for a cancer 
to evolve, progress, and metastasize [2, 11, 12]. Malignant 
cells may evade the many innate and adaptive defense 
mechanisms and eventually give rise to neoplasms, due 
to their ability to induce immune suppression and to 
control and redirect the functions of several of the stromal 
cells, shaping a symbiotic local environment [11] which 
basically takes the character of an inflammatory reaction, 
a recognized hallmark of cancer [3, 13]. Although the 
stroma is the arena for numerous opposing stimulatory 
and inhibitory mechanisms [14–17], the very existence 
of the tumor reveals its escape from the host defense, 
and many lines of evidence strongly suggest that the 
microenvironment is largely tumor-promoting at all stages 
of cancer [2, 11, 18]. 
A tumor-promoting inflammatory microenvironment 
is driven by interactions between the malignant cells, 
immune cells, and other stromal cells, which communicate 
through numerous growth factors, cytokines, and other 
locally active agents [18, 19]. These factors are essential 
for tumor growth, progression, and metastasis [11, 20]. 
In addition, some of the pro-inflammatory factors may 
exert effects that go beyond the local tumor, causing a 
state of systemic inflammation [11, 21], which is strongly 
implicated as an important cause of cancer-associated 
morbidity, in terms of pain, fatigue, functional disability, 
anorexia, and cachexia, as well as reduced treatment 
response and poor survival [5, 6, 22, 23]. 
Interleukin-6 (IL-6) is an important pro-
inflammatory cytokine produced particularly by 
macrophages but also by other stromal cells such as 
neutrophils, cancer-associated fibroblasts and endothelial 
cells, as well as some cancer cells [24]. IL-6 exerts its 
effects on many cells [25, 26] through its receptor IL-6R 
with the associated gp130 and downstream mechanisms 
where JAK-STAT3 is a major pathway [19, 27]. IL-6 
has a main role in sustaining chronic inflammation [28], 
and it is a potent inducer of hepatic synthesis of acute 
phase proteins, including C-reactive protein (CRP) [29]. 
Furthermore, several lines of evidence implicate IL-6 as 
a promoting factor in cancer [30–33] and suggest that IL-
6 contributes to a chronic inflammatory and tumorigenic 
microenvironment in CRC [19, 34]. There are also reports 
showing that high IL-6 is associated with poor prognosis 
in CRC [35].
Measurable systemic effects of inflammation have 
been termed systemic inflammatory response (SIR). 
Different blood measures for SIR have been proposed 
[8, 9, 36, 37]. The relationship between these measures 
and tumorigenic inflammatory processes in CRC is not 
fully clarified. There is a need of further studies of the 
prognostic significance of different markers of SIR. The 
levels of SIR markers, such as the modified Glasgow 
Prognostic Score (mGPS), the derived neutrophil to 
lymphocyte ratio (dNLR), platelet levels, CRP levels, 
and high-sensitive CRP (hs-CRP) have all been found 
to predict cancer-specific survival [8, 37, 38]. Most of 
these studies come from cohorts of patients treated with 
curative surgery, and only a few reports focus on patients 
with metastatic cancer. It was recently reported that high 
hs-CRP levels predict poor survival in mCRC [38]. Little 
is known about the impact of inflammation in mutation 
subgroups in this cancer. The present study was based 
on a cohort from the NORDIC-VII study with patients 
receiving first-line treatment for mCRC [39]. The aim 
was to explore the prognostic role of serum IL-6 and CRP 
levels, in the total study population as well as in subgroups 
according to RAS and BRAF mutation status, and to study 
the value of prognostic inflammatory markers for use in 
daily clinical practice. 
RESULTS 
Baseline characteristics 
Between May 2005 and October 2007, patients with 
untreated mCRC were enrolled in the NORDIC-VII study, 
randomized to first line treatment with standard Nordic 
FLOX, cetuximab and FLOX, or cetuximab combined 
with intermittent FLOX [39]. In the present study, the 
data were analyzed across the different treatment arms. 
Baseline demographics and clinical characteristics of the 
393 patients included in this study are shown in Table 1. 
Analysis regarding tumor burden and site of 
metastases in relation to IL-6 and CRP show that the 
distribution of  inflammatory markers was relatively 
similar in the different groups, see Supplementary Table 1. 
Overall prognostic value of IL-6 in mCRC
High pretreatment levels of serum IL-6 were 
strongly associated with impaired survival. Figure 1 
shows that patients with high versus low IL-6 levels 
(dichotomized at median 5.6 pg/ml) had a median PFS of 
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Table 1: Baseline patient demographics and clinical characteristic, n = 393
Characteristics Median (range)
Age, years 62.1 (24.1–74.9)
                                                              Number (%)
Sex
 male
 female
237 (60.3)
156 (39.7)
WHO performance status
 0
 1
 2
255 (64.9)
114 (29.0)
 24 (6.1)
Location
 colon
 rectum
233 (59.3)
160 (40.7)
No.of metastatic site
 1
 > 1
123 (31.3)
270 (68.7)
Primary tumor resected
 no
 yes
 95 (24.2)
298 (75.8)
Liver only
 yes
 no
 82 (20.9)
311 (79.1)
Alkaline phosphatase
 normal
 abnormal
212 (53.9)
181 (46.1)
Prior adjuvant chemotherapy  42 (10.7)
Figure 1: Kaplan-Meier curves for progression-free survival (A) and overall survival (B), stratified by IL-6 serum level 
(dichotomized at median, ≤ 5.6, > 5.6 pg/ml). 
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7.7 versus 8.9 months, respectively (HR = 1.54, 95% CI 
1.25–1.91, P < 0.001), and a median OS of 16.6 versus 
26.0 months (HR = 1.92, 95% CI 1.56–2.37, P < 0.001). 
The prognostic role of baseline levels of IL-6 on OS was 
also confirmed in a model adjusting for other prognostic 
markers and clinical characteristics (CEA, mutation status, 
ALP and WHO performance status). Adding treatment 
arm or interaction between treatment arm and IL-6 in the 
analysis did not provide extra information. Sensitivity 
analysis with other cut-offs than the median for IL-6 gave 
essentially the same results. 
Prognostic role of IL-6 in subgroups according 
to RAS and BRAF mutation status
The data indicated that the prognostic role of IL-6 
differed depending on the RAS and BRAF mutation status, 
with a statistically significant interaction in unadjusted 
and adjusted analyses, P = 0.004 (Table 2). There was a 
much larger relative reduction in survival associated with 
high IL-6 in the BRAF-mutated group, as analyzed with 
Cox regression for OS (HR = 4.05, 95% CI 2.13–7.71), 
compared to the double wild-type (HR = 1.44, 95% CI 
1.00–2.06)  and the RAS-mutated groups (HR = 1.23, 95% 
CI 0.88–1.72 ). Median PFS and OS for patients with 
high versus low IL-6, sub-classified according to RAS and 
BRAF mutation status are summarized in Table 3. 
Comparison of inflammatory markers and 
correlation with IL-6
The prognostic role of the different markers of 
SIR studied here, i.e. mGPS, dNLR, platelets, and CRP, 
in terms of PFS and OS, was examined. The results 
showed that for all these SIR markers high levels were 
associated with poor outcome, and no statistically 
significant differences in their prognostic value were 
detected (Table 4). Only CRP was used as a SIR biomarker 
in the further analyses. Supplementary Figure 1 shows a 
positive correlation between values of serum CRP and 
IL-6 (r = 0.66, P < 0.001), indicating that about 40% of 
the variability in the CRP values could be accounted for 
by IL-6.  The frequency distribution of CRP and IL-6 
levels was similar in the different mutation subgroups 
(Table 3). Neither were there any major differences in the 
distribution of platelets, dNLR, and mGPS overall or for 
the different subgroups, see Supplementary Table 2.
Prognostic value of CRP 
High levels of CRP were associated with short 
survival. Figure 2 shows that in the four categories of 
baseline serum CRP level (≤ 10, 11–30, 31–60 and > 60 
mg/L), median PFS was 8.9, 7.6, 8.2, and 6.6 months, 
respectively (log rank test, P < 0.001) and median OS 
was 24.3, 20.6, 17.1, and 12.3 months, respectively (log 
rank test, P < 0.001). The prognostic role of baseline 
serum CRP in terms of OS was also confirmed in a 
model adjusted for other prognostic markers and clinical 
characteristics (CEA, mutation status, ALP and WHO 
performance status) (HR 1.16, 95% CI 1.03–1.30, 
P = 0.015),  see Supplementary Table 3. Adding treatment 
arm in the analysis gave no additional information.
Median PFS and OS for patients with different CRP 
levels according to mutation status are summarized in 
Table 3. OS for patients with CRP values under 10 mg/L 
compared to CRP values over 60 mg/L were 33.8 
versus 12.8 months in the wild-type group, 20.5 versus 
14.2 months in the RAS mutated group and 14.1 versus 
3.8 months in the BRAF mutated group. Although these 
relationships between serum levels of CRP and treatment 
outcome largely followed the same pattern as for IL-6 
in the subgroups of RAS and BRAF mutation status, the 
interaction between mutation status and different CRP 
levels was not statistically significant. 
Changes in CRP and IL-6 over time
Having shown that baseline levels of both serum 
IL-6 and CRP have statistically significant impact on 
survival, we further explored whether changes in IL-6 and 
CRP over the first 8 weeks of treatment would improve 
the prognostic value of the markers. Mutation status did 
not significantly affect the distribution of change in either 
inflammatory marker. The distribution of change in CRP 
was also similar in the three arms, but the proportion of 
patients with a reduction in IL-6 was slightly higher in 
arm A (Supplementary Table 4).  Several exploratory 
analyses with different measures of changes over time 
were performed. None of the models including changes 
in serum IL-6 or CRP over 8 weeks improved prediction 
of PFS or OS over models including baseline IL-6 or CRP 
only (Supplementary Table 5). 
DISCUSSION 
This study adds to the evidence of a role of 
inflammatory processes in cancer, as it demonstrates that 
high levels of inflammation biomarkers predict markedly 
impaired survival in a large cohort of patients with 
mCRC. Furthermore, it provides more results to support 
the involvement of IL-6 in tumor-promoting inflammation 
in this malignancy, and the data also suggest that IL-6 
interacts differentially with the tumorigenic mechanisms 
of  mutated BRAF and RAS in CRC. Finally, the study 
demonstrates that CRP, which is easily available in routine 
clinical practice, is a useful prognostic biomarker in this 
disease.
The role of IL-6 in inflammation and in the 
pathogenesis of various human diseases is well 
documented [25, 26, 40]. In cancer, IL-6 is produced by 
several cells in a tumor and can exert its pleiotropic effects 
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on both malignant and stromal cells [30, 41]. This is the 
case for both sporadic and inflammation-associated CRC 
[7, 19, 30, 34, 41]. In the present study of patients with 
mCRC, we found that high serum concentrations of IL-6 
were associated with markedly impaired prognosis. 
Furthermore, the finding that a high level of IL-6 
was associated with a particularly large relative reduction 
in survival in patients with mutated BRAF, unlike mutated 
RAS, is worth noting. Although the molecular explanation 
for this is not known, it might reflect differences in the 
way IL-6 interacts with the tumorigenic mechanisms 
activated by the mutated BRAF and mutated RAS. 
The serine/threonine kinase BRAF, which is activated 
dramatically by the V600E mutation [42], is a selective 
activator of the MEK/ERK pathway, a major mediator 
of cell cycle entry. IL-6 primarily stimulates pro-
inflammatory pathways, notably JAK/STAT signaling, 
which exerts several potentially tumor-promoting effects, 
Table 2: Multivariable cox regression analysis for OS including interaction term for IL-6 and RAS 
and BRAF mutation status  in 364 patients 
Variable
Adjusted analysis, IL-6
HR 95% CI P-value
Mutation status IL-6
pg/ml
RAS / BRAF WT
(n = 154)
≤ 5.8 
> 5.8
1
1.44 1.00–2.06
0.004*
RAS Mut
(n = 167)
≤ 5.8 
> 5.8
1
1.23 0.88–1.72
BRAF Mut
(n = 43)
≤ 5.8 
> 5.8
1
4.05 2.13–7.71
CEA mg/L
< 5 (n = 70)
≥ 5 (n = 294)
1
1.68 1.23–2.30 < 0.001
ALP 
Normal (n = 195)
Abnormal (n = 169)
1
1.58 1.24–2.01 < 0.001
WHO performance status
0 (n = 235)
1 (n = 105)
2 (n = 24)
1
1.29
2.70
1.00–1.66
1.71–4.26
< 0.001
0.048
< 0.001
Abbreviations: Mut, mutant; WT, wild- type; OS, overall survival; CEA, Carcinoembryonic antigen; ALP, Alkaline 
phosphatase * interaction P.
Figure 2: Kaplan-Meier curves for progression-free survival (A) and overall survival (B), stratified by CRP serum 
level (≤ 10, 11–30, 31–60 and > 60 mg/L).
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including angiogenesis and enhanced invasive capacity 
[33, 40]. It is likely that these complementary mechanisms 
may form a basis for synergism. In contrast, mutated RAS 
can mediate enhanced activity in several pathways [43], 
leading to stimulation not only of the ERK cascade but 
also the PI3K/Akt and other pathways, with downstream 
mechanisms that may enhance inflammatory processes, 
and it is conceivable that a pro-inflammatory stimulus 
from IL-6 may have a somewhat weaker impact on a RAS-
driven malignancy.   
A major aim of this study was to examine the 
prognostic potential of easily available markers of 
inflammation in mCRC. It was found that the level of 
CRP was a strong prognostic predictor in mCRC, in 
agreement with data recently reported by others [38]. 
Regarding survival, CRP was an equally good marker 
as dNLR, mGPS and platelets. The median OS was 33.8 
months in patients whose tumors were double wild-type 
and who had normal CRP and 12.8 months in the highest 
CRP group.  Corresponding results for mutated RAS and 
mutated BRAF groups were 20.5 versus 14.2 and 14.1 
versus 3.8 months, respectively. However, the interaction 
between RAS or BRAF mutation status and CRP value, 
unlike IL-6, was not statistically significant. This and the 
fact that the correlation between IL-6 and CRP, although 
statistically significant, was not very strong, indicate that 
CRP likely reflects a broader measure of the inflammatory 
status than IL-6. 
The marked difference in OS for high versus 
low IL-6 or CRP despite relatively small differences in 
PFS is consistent with data indicating a special role of 
inflammation in advanced and cachectic cancer [5, 23]. 
Baseline serum IL-6 and CRP levels were better predictors 
of survival than changes in IL-6 and CRP levels during 
treatment. This probably reflects distinct phenotypes from 
early stages of the tumor development. 
The inflammatory burden is likely responsible for 
clinical effects such as weight loss and poor performance 
status [9, 22, 23]. Like some of the other established 
markers of SIR, CRP has the advantage of being 
inexpensive, and it can be measured routinely both in daily 
clinical practice and in study settings, making it easily 
accessible, and, in addition, it is also readily and precisely 
quantifiable [36]. Since increasing CRP values confer an 
increasingly worse prognosis independent of other well-
known prognostic markers, CRP adds important clinical 
value. Combining information on CRP and mutation 
status provides improved prognostic information that 
may guide treatment decisions concerning the need for 
aggressive first-line treatment for some patients. On the 
other hand, some patients with BRAF mutation combined 
with elevated CRP have a very poor prognosis and might 
have limited benefit from chemotherapy. 
The main strength of this study is that it is large 
and analyzes multiple markers of SIR in a cohort of 
prospectively collected data from patients with mCRC. 
Most previous reports of systemic inflammation come 
from cohorts of cancer patients treated with surgery, and 
only a few reports focus on patients with unresectable 
metastatic cancer. The size of this study provides the 
opportunity to compare different markers of SIR and 
also allows analysis of the prognostic role of IL-6 and 
inflammation as related to mutation status.  However, 
there are also several limitations, as not all variables were 
available for all patients, and data on possible ongoing 
infections are lacking.    
In conclusion, serum IL-6 and CRP are good 
prognostic biomarkers in patients with mCRC independent 
of the RAS and BRAF mutation status. The effect of IL-6 
was particularly pronounced in patients with BRAF 
mutation. Combining the prognostic information of CRP 
and IL-6 with knowledge of the RAS and BRAF mutation 
Table 3: Median PFS and OS, subclassified according to RAS and BRAF mutation status in 
393 patients
PFS OS
   
                        RAS/BRAF 
           WT
                         RAS 
                        Mut
                          BRAF 
                          Mut
  RAS/BRAF 
WT
RAS 
Mut
BRAF 
Mut
n (%)
Median 
(months)
95% CI n (%)
Median 
(months) 
95% CI n (%)
Median 
(months) 
95% CI
 Median 
(months) 
95% CI
 Median
(months)
95% CI
Median
(months)
95% CI
IL-6, pg/ml
≤ 5.6
> 5.6
79 (47.0)
89 (53.0)
10.9 (8.5–13.3)
  8.4 (7.4–9.5)
P < 0.001
97 (54.2)
82 (45.8)
8.2 (7.5–8.8)
7.8 (6.8–8.8)
P = 0.364
19 (41.3)
27 (58.7)
9.0 (3.6–14.3)
4.6 (3.0–6.3)
P < 0.001
35.3 (25.3–45.3)
20.5 (18.8–22.3)
P < 0.001
23.4 (19.3–27.5)
16.6 (14.2–19.1)
P = 0.002
17.0 (6.9–27.0)
  6.9 (4.7–9.2)
P < 0.001
CRP, mg/L
≤ 10
11–30
31–60
> 60
69 (41.1)
49 (29.2)
26 (15.5)
24 (14.3)
10.9 (7.9–13.9)
  9.3 (8.2–10.4)
  9.2 (6.5–11.9)
  7.3 (5.6–9.0)
P = 0.005
  
83 (46.4)
48 (26.8)
20 (11.2)
28 (15.6)
8.3 (7.7–8.9)
6.7 (5.6–7.9)
7.1 (4.6–9.5)
6.8 (4.7–9.0)
P = 0.089
  
21 (45.7)
10 (21.7)
  7 (15.2)
  8 (17.4)
6.9 (4.6–9.2)
5.4 (2.7–8.1)
5.8 (1.2–10.2)
1.8 (0–4.5)
P = 0.054
33.8 (26.2–41.4)
22.6 (12.3–32.9)
20.5 (15.4–25.6)
12.8 (9.2–16.3)
P < 0.001
20.5 (16.0–24.9)
20.6 (14.8–26.4)
16.2 (11.7–20.7)
14.2 (5.2–23.1)
P < 0.009
14.1 (8.4–19.9)
  8.1 (5.1–11.1)
  7.6 (4.2–11.0)
  3.8 (2.1–5.5)
P < 0.008
Abbreviations: PFS, progression-free survival; OS, overall survival; IL-6, Interleukin 6; CRP, C-reactive protein; WT, wild- type; Mut, mutant.
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status may help in treatment decisions. It is conceivable 
that patients with high serum IL-6 might benefit from 
treatment interrupting the inflammation, and drugs 
targeting the IL-6/IL-6R axis might be a future treatment 
option in CRC [6, 34, 44, 45].
MATERIALS AND METHODS 
Patients
The randomized NORDIC-VII study [39] 
investigated the effects of combining cetuximab with 
a regimen of bolus 5-flourouracil (5-FU)/folinic acid 
(FA) and oxaliplatin (Nordic FLOX) [46] in first-line 
therapy of mCRC. Patients were randomly assigned to 
receive standard Nordic FLOX, cetuximab and FLOX, 
or cetuximab combined with intermittent FLOX. Since 
there was no statistically significant difference in outcome 
between the treatment arms, neither in the original analysis 
[39] nor in subsequent updated overall survival data until 
April 30, 2014 (unpublished data), the present study 
used the whole patient population across the different 
treatments in NORDIC-VII.
RAS and BRAF mutation status was available for 
393 patients. Of these 364 patients were eligible for the 
multivariable analysis of clinical and prognostic markers, 
whereas 374 patients were eligible for the comparison of 
different markers of SIR with available albumin, CRP, 
platelets, neutrophils and leukocytes at baseline. Measures 
of both serum IL-6 and CRP at baseline and at week 8 
were available for 393 and 275 patients, respectively. 
Mutation status (RAS, RAF, double wild-type) was 
obtained for the whole study population. 
Collection of blood samples and IL-6 
measurement
WBC, ANC, platelet count and hemoglobin were 
measured at baseline and before each treatment cycle. 
Albumin was analysed at baseline and every second cycle 
and CRP was measured at baseline, after one week and 
then before every cycle for four cycles and every fourth 
cycle thereafter. The analyses were conducted according 
to current practice at each participating hospital. Fresh-
frozen serum/plasma samples were collected at baseline, 
after the first week of cycle 1, after the second week 
of cycle 1 and after the second week of cycle 4. Serum 
concentration of IL-6 was determined in serum samples 
stored at minus 80°C by a commercially available human 
IL-6 high-sensitive enzyme-linked immunosorbent assay 
(ELISA, Quantikine HS, high sensitive, R&D Systems, 
Abingdon, Oxon, UK) [47].
Mutation analyses of KRAS, NRAS and BRAF 
Genomic DNA was extracted from formalin-fixed 
paraffin-embedded (FFPE) 10 µm tissue sections with 
65% to 70% (median) tumour cells using QIAamp DNA 
Table 4: Prognostic information in terms of PFS and OS of different markers of systemic 
inflammatory response (SIR) in 374 patients
                   
                               n (%)
PFS OS
HR                  95%CI         P-value HR         95% CI              P-value
CRP (mg/L)
≤ 10
11–30
31–60
> 60
165 (44.1)
100 (26.7)
  51 (13.6)
  58 (15.5)
   
   1
1.63
1.45
1.82
1.25–2.12
1.04–2.01
1.33–2.49
< 0.001
< 0.001
   0.027
< 0.001
1
1.38
1.88
2.45
1.06–1.79
1.35–2.62
1.79–3.35
     < 0.001
     0.016
     < 0.001
     < 0.001
Platelets( 109/ L)
≤ 400
> 400
266 (71.1)
108 (28.9)
   1
1.60 1.27–2.02 < 0.001
1
1.85 1.47–2.34      < 0.001
mGPS
0
1
2
165 (44.1)
166 (44.4)
  43 (11.5)
   1
1.55
1.99
1.23–1.95
1.40–2.81
< 0.001
< 0.001
< 0.001
1
1.60
2.16
1.27–2.01
1.52–3.06
     < 0.001
     < 0.001
     < 0.001
dNLR
≤ 2.1
> 2.1
187 (50.0)
187 (50.0)
   1
1.56 1.25–1.93    < 0.001
1
1.68 1.35–2.08      < 0.001
Abbreviations: CRP, C-reactiv protein; mGPS, Modified Glasgow Prognostic Score: 0 = CRP ≤ 10 mg/L  (independent of 
the albumin level), 1 = CRP > 10 mg/L and albumin ≥ 35 g/L, 2 = CRP > 10 mg/L and albumin < 35 g/L;  dNLR, Derived 
Neutrophil to Lymphcyte Ratio.
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Micro Kit (Cat.56304, Quiagen). Tumour DNA was 
screened for the presence of the KRAS mutations Q61H, 
Q61L, Q61R, K117X (K117N 351A > C, K117N 351A > 
T, K117R, K117E) and A146X (A146T, A146P, A146V) 
using the KRAS Mutation Analysis Kit for Real-Time PCR 
(exons 2, 3 and 4) by EntroGen. The NRAS mutations 
G12C, G12D, G12S, G13V, G13R, Q61K, Q61R, 
Q61L, Q61H and A146T were analyzed using the NRAS 
Mutation Analysis kit (EntroGen). The mutation detection 
assays and the analysis of the results were performed in 
accordance with the manufacturer’s instructions. Input in 
the KRAS and NRAS assays were 10 ng and 20 ng DNA, 
respectively. Analyses for the BRAF V600E mutation was 
performed as described by Hamfjord et al. [48]
Markers of SIR 
dNLR, platelet counts, mGPS, and CRP were chosen 
as clinically useful markers of SIR. dNLR was applied 
with the assumption that white blood cell counts is made 
up primarily of lymphocytes and neutrophils, and that the 
white cell count minus neutrophil count would be quite 
similar to the lymphocyte count [37]. Separate analyses 
of the prognostic effect of each different inflammatory 
marker on PFS and OS were performed. Patients were 
grouped into four CRP categories (≤ 10, 11–30, 31–60, > 
60 mg/L), based upon current reference cut-off values in 
colon cancer [36]. dNLR was dichotomized at the median 
value 2.1, as no consensus regarding cut-off values exists in 
the literature, but in accordance with previous publications 
[37]. Platelet counts were dichotomized at below or above 
400 ·109/ L. mGPS was classified from 0-2, 0 defined 
as CRP ≤ 10 mg/L (independent of the albumin level), 1 
defined as CRP > 10 mg/L and albumin ≥ 35 g/L, and 2 
defined as CRP > 10 mg/L and albumin < 35 g/L [49]. IL-6 
levels were dichotomized at the median 5.6 pg/ml, as no 
consensus exists in the literature concerning cut-off value 
[30]. Reported median serum IL-6 in healthy subjects was 
1.4pg/ml [47]. The results of IL-6 and mutation analyses 
are presented in accordance with REMARK (Reporting 
Recommendations for Tumor Marker Prognostic Studies) 
guidelines [50]. The remaining analyses were conducted 
according to current practice at each participating hospital. 
Ethics
The NORDIC-VII study (http://clinicaltrials.gov/
show/NCT00145314) was approved by the national ethics 
committees and governmental authorities in each country 
and conducted in accordance with the Declaration of 
Helsinki. All patients gave written informed consent.
Statistical analysis 
The statistical analyses were performed using IBM 
SPSS (version 18.0. Chicago: SPSS Inc.). Demographic 
data were described with median and range (continuous 
variables) and with proportion and percentages 
(categorical variables). The prognostic values of different 
categories of IL-6 and CRP values were assesed by 
Kaplan-Meier plots, log-rank test, and Cox proportional 
hazards model. Separate analyses of the effect of IL-6, 
CRP, CEA, ALP, WHO performance status, mutation 
status, platelets, WBC, ANC, metastatic site, number of 
metastatic sites, sex, tumor location, treatment arm and 
age were performed. Only variables statistically significant 
in these analyses were included in the multivariable 
analyses and models were restricted to include statistically 
significant variables only. Correlation between IL-6 and 
CRP was estimated with Pearson`s r using log-transformed 
values to ensure an approximately linear association. An 
interaction term was included in the Cox model to explore 
the effect of mutation status on the prognostic effect of 
IL-6 and CRP, respectively. Several different measures 
of change in CRP and IL-6 over 8 weeks; absolute and 
relative difference, as well as various categorizations were 
explored and compared using landmark analysis. Model 
fit was compared by likelihood ratio tests, and the model 
finally chosen was the one resulting in the best fit. 
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